Identification of Multiple HPV Types on Spermatozoa from Human Sperm Donors by Kaspersen, Maja D. et al.
Identification of Multiple HPV Types on Spermatozoa
from Human Sperm Donors
Maja D. Kaspersen
1, Peter B. Larsen
2, Hans Jakob Ingerslev
3, Jens Fedder
4, Gert Bruun Petersen
2, Jesper
Bonde
5, Per Ho ¨llsberg
1*
1Department of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark, 2Cryos International Sperm Bank, Aarhus, Denmark, 3The Fertility Clinic,
Aarhus University Hospital, Aarhus, Denmark, 4Laboratory of Reproductive Biology, Scientific Unit and Fertility Clinic, The Regional Hospital Horsens, Horsens, Denmark,
5Pathology Division, Clinical Research Center, Hvidovre Hospital, Hvidovre, Denmark
Abstract
Human papillomaviruses (HPV) may cause sexually transmitted disease. High-risk types of HPV are involved in the
development of cervical cell dysplasia, whereas low-risk types may cause genital condyloma. Despite the association
between HPV and cancer, donor sperm need not be tested for HPV according to European regulations. Consequently, the
potential health risk of HPV transmission by donor bank sperm has not been elucidated, nor is it known how HPV is
associated with sperm. The presence of 35 types of HPV was examined on DNA from semen samples of 188 Danish sperm
donors using a sensitive HPV array. To examine whether HPV was associated with the sperm, in situ hybridization were
performed with HPV-6, HPV-16 and -18, and HPV-31-specific probes. The prevalence of HPV-positive sperm donors was
16.0% and in 66.7% of these individuals high-risk types of HPV were detected. In 5.3% of sperm donors, two or more HPV
types were detected. Among all identified HPV types, 61.9% were high-risk types. In situ hybridization experiments
identified HPV genomes particularly protruding from the equatorial segment and the tail of the sperm. Semen samples from
more than one in seven healthy Danish donors contain HPV, most of them of high-risk types binding to the equatorial
segment of the sperm cell. Most HPV-positive sperm showed decreased staining with DAPI, indicative of reduced content of
DNA. Our data demonstrate that oncogenic HPV types are frequent in men.
Citation: Kaspersen MD, Larsen PB, Ingerslev HJ, Fedder J, Petersen GB, et al. (2011) Identification of Multiple HPV Types on Spermatozoa from Human Sperm
Donors. PLoS ONE 6(3): e18095. doi:10.1371/journal.pone.0018095
Editor: Jean-Luc Darlix, Institut National de la Sante ´ et de la Recherche Me ´dicale, France
Received September 6, 2010; Accepted February 21, 2011; Published March 29, 2011
Copyright:  2011 Kaspersen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by The University Hospital of Aarhus; The Lundbeck Foundation; The Faculty of Health Sciences, Aarhus University. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ph@microbiology.au.dk
Introduction
The family of human papillomavirus (HPV) encompasses more
than 100 types, of which 40 have been isolated from the genital
tract [1]. A number of these (HPV-16, -18, -26, -31, -33, -35, -39,
-45, -51, -52, -53, -56, -58, -59, -66, -68, -70, -73, -82, and -85) are
grouped as high-risk types, because they are involved in the
development of cervical neoplasia in persistently infected women
[2]. Of these types, only HPV-16 and -18 are included in the HPV
vaccines. Thus, HPV remains a risk factor for cervical neoplasia in
vaccinated women. In addition, a number of low-risk types are
also sexually transmitted and may cause genitial condyloma [3].
Despite the clinical importance of HPV in lower genital tract
cancers, little attention has been given to the transmission of
HPV through semen. Several studies have identified HPV in
human semen, mainly from men recruited at fertility or
maternity clinics, with a prevalence ranging from 4.5–64.3%
[4,5,6,7,8,9,10,11,12,13]. The variability reflects differences in
clinical characteristics and limitations in both the number of
analyzed study subjects and HPV types. Whether or not the
presence of HPV in semen has consequences for sperm
functionality has yet to be resolved. Conflicting conclusions have
been drawn regarding sperm concentration, motility, and vitality
as well as semen volume and pH [4,5,10,14,15,16,17,18,19].
HPV may potentially enter the uterus transmitted by sperm.
Attempts to wash off HPV DNA from sperm have failed
[9,12,16], suggesting either a very strong binding of HPV to a
receptor on the sperm cell surface or an entrance of HPV into the
sperm cell. Indeed, sperm-associated HPV DNA fragments have
been isolated from mouse blastocysts and cells of the murine
endometrium [20], and HPV E6 mRNA sequences has been
detected in sperm cell specimens [21]. Whether or not human
sperm express a specific receptor for HPV is not known, but
Pe ´rez-Andino et al. [22] demonstrated recently that HPV-16
capsids adsorb to distinct sites on the sperm head surface at the
equatorial segment, suggesting that these sites may mediate HPV
binding.
The use of semen from sperm banks for insemination highlights
the importance of knowing the risk of attracting HPV infections
during these procedures. The prevalence by which donor semen
contains HPV high-risk types not covered by the current HPV
vaccines becomes important, since semen samples are not required
to be tested for the presence of HPV. We therefore examined the
prevalence and types of HPV in 188 semen donors using a
sensitive array technology. Finally, we provide evidence for in vivo
association of HPV with a specific region on the sperm head
surface. Noticeably, HPV-positive sperm had decreased amount of
DNA.
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Ethics statement
The study was conducted according to the Helsinki declaration
and the sperm donors had signed a declaration of consent stating
that the donated semen may be used for scientific intentions.
Samples were anonymized and no information is referable to any
individual. The Ethical Committee of Science for the Region of
Middle Jutland has approved the study (M-20100238).
Donors and samples
A total of 267 semen samples from 188 sperm donors were
obtained from three Danish units of Cryos International Sperm
Bank. From 34 of the donors, multiple ejaculates were examined:
two samples were examined from 21 donors, three samples from 5
donors, four samples from 2 donors, seven samples from one
donor, eight samples from 4 donors, and ten samples from 1
donor. Seventy-four (39.4%) of these samples were from first time
donors not yet approved for sperm donation and therefore
unselected and representing the general male population, whereas
the remaining 114 samples came from approved active sperm
donors. The only exclusion criterion for the first-time donors was
no sperm. Approved donors had been examined and excluded if
they had a predisposition to certain inheritable diseases (http://dk.
cryosinternational.com/clinics/screening.aspx), previous known
genital infections, current infection of C. trachomatis or N. gonorrhoae
(swab), or sero-positivity towards human immunodeficiency virus
type1 and 2, human T-cell lymphotropic virus type 1 and 2,
hepatitis B and C, and T. pallidum. The age range of the donors at
the time of sperm donation was 18 to 48 years, with a mean age of
25 years (SD=6.1). Donors are not selected based on ethnicity
and therefore probably reflect that of the general Danish
population of young men.
Sperm sample handling and DNA extraction
Semen samples were visually analyzed, frozen in liquid nitrogen
either untreated or after addition of 0.33 mL SpermCryos
Allround (SCA) freeze medium (ProVitro, Odense, Denmark)
per 1 mL semen, and stored at 2196uC until further analysis.
DNA was extracted using a Qiagen DNA extraction kit (Qiagen,
Copenhagen, Denmark) and the robotic QiaCube (Qiagen)
according to the manufacturer’s instructions.
Figure 1. HPV frequency and type distribution in Danish donor semen, analyzed using a sensitive HPV type-specific array. (A):
Frequency of twenty high-risk types, given as percent of all tested donors. (B): Frequency of fifteen low-risk types, given as percent of all tested
donors.
doi:10.1371/journal.pone.0018095.g001
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HPV type-specific DNA fragments of 380–450 base pairs were
amplified using type specific primers for the conserved L1
region. During amplification, the products were labelled with
biotin. HPV-positivity of the samples was determined using the
CLART HPV 2 Clinical Array (Genomica, Madrid, Spain) [23].
This array is based on the identification of biotinylated PCR
products on a 262 mm glass platform, which is divided into 120
immobilized cDNA spots, coated with probes specific for one of
35 HPV types in non-grouped triplicates. The biotinylated
products hybridize to their specific probes, and the biotin on the
amplified and immobilized probes are recognized by a
peroxidase-conjugated streptavidin. The array design includes a
control for the presence of genomic DNA consisting of an 892
base pair PCR amplification of the humane cystic fibrosis
transmembrane conductance regulator (CFTR) gene, and an
amplification control consisting of plasmid CFTR of 1202 base
pairs. The CLART HPV 2 Clinical Array detects with high
sensitivity low risk HPV types 6, 11, 40, 42, 43, 44, 54, 61, 62,
71, 72, 81, 83, 84, 89, and high-risk HPV types 16, 18, 26, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82, and 85.
The procedure involves an initial denaturation of DNA by
incubation at 95uC for 10 min followed by an immediate cooling
on ice. The denatured products were diluted 1:20 in Hybridiza-
tion Solution Buffer, and 100 ml was added to each prewashed
array well. The probes were allowed to hybridize at 60uCo na
thermomixer for 1 hour. The wells were washed twice with wash
buffer and then incubated with a simultaneously blocking and
conjugating buffer at 30uC for 15 min on a shaking thermo-
mixer. Subsequently, the wells were washed three times before
addition of 100 ml Developer per well. The developing process
was carried out without agitation at 25uC for 10 min, and
immediately read by a Clinical Arrays Reader. The CLART
HPV 2 Clinical Array has been developed for diagnostic use.
According to the product information, this array performs with a
diagnostic sensitivity of 100% for 29 of the HPV types, .91%
for 5 types, and with undetermined specificity for type 85. The
Genomica CLART assay was chosen because of the great
robustness and reliability of this assay. The Clinical Research
Center, Pathology Division, Hvidovre Hospital, participated in a
recent quality assurance panel distributed by the WHO Lab Net
Work. The results demonstrated that the CLART assay in our
Figure 2. Longitudinal analysis of HPV-positive sperm samples. HPV is not continuously shed in semen. Circles on a relative time scale image
series of ejaculates from 6 different donors, occasionally positive for an HPV. Filled circles represent HPV positive samples; open circles represent HPV
negative samples. Starting points are given by the first analyzed ejaculate for each donor. Series of ejaculates from six different donors were found
positive for HPV type 84; type 53, 31, and 52; type 62; type 61; type 54; and type 52, respectively.
doi:10.1371/journal.pone.0018095.g002
Figure 3. In situ hybridization on human sperm using HPV
type-specific probes. Specific hybridizations are indicated by arrows.
(A–C): In situ hybridization on an HPV-16 positive sperm sample using a
probe specific for HPV-16. The sample in picture A was simultaneously
background stained with hematoxylin. (D–I): In situ hybridization on an
HPV-6 positive sperm sample using a probe specific for HPV-6. (J–L): In
situ hybridization on an HPV negative sperm sample using a probe
specific HPV-6. This figure is a representative of three independent in
situ hybridization experiments using two different HPV-6 positive
samples and two different HPV-16 positive samples.
doi:10.1371/journal.pone.0018095.g003
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.5000 copies in 5 mlH 2O.
In situ hybridization
HPV type 16 and 6 were visualized in sperm by in situ
hybridization using a ZytoFast HPV-Typing Kit (ZytoVision,
Bremerhaven, Germany). The in situ hybridization procedure was
carried out according to the manufacture’s instructions. Briefly,
10 ml raw semen were smeared and allowed to air dry on a
Thermo Scientific Superfrost Plus object glass (Thermo Scientific,
Copenhagen, Denmark) and fixed in 4% (v/v) formalin. The cells
were treated with a Pepsin Solution for 5 min at 37uC, and the
proteolytic reaction was stopped in 100% ethanol, after which the
cells were rinsed in deionized water. Hybridization of biotinylated
HPV type 16 and 6 specific DNA probes was carried out with an
initial denaturation for 10 min at 75uC, and hybridization for
1 hour at 37uC. Unhybridized probes were removed by washing
in TBS and distilled water, and AP-anti-Biotin and AP-substrate
were consecutively applied, each with a 30 min incubation at
37uC. Positive and negative controls for HPV-16 detection were
included in the form of sections of tonsil biopsies. Cover slips were
mounted with a mix of polyvinyl alcohol and glycerol, and the
microscope slides were analyzed on a Leica LEITZ DM
microscope with a 1006magnification.
Fluorescence in situ hybridization
The HPV types 6, 16, 18, and 31 were visualized in sperm by
fluorescence in situ hybridization (FISH) using the above-
mentioned ZytoFast HPV-Typing Kit (ZytoVision, Bremerhaven,
Germany) and a PE-conjugated streptavidin (BD Biosciences
Pharmingen, San Diego, CA). The FISH procedure was carried
out according to the instructions of the ZytoFast HPV-Typing Kit
with few modifications. Briefly, 20 ml raw semen were smeared
and allowed to air dry on a Thermo Scientific Superfrost Plus
object glass (Thermo Scientific, Copenhagen, Denmark) and fixed
in 4% (v/v) formalin. The cells were treated with a Pepsin Solution
for 5 min at 37uC, and the proteolytic reaction was stopped in
100% ethanol, after which the cells were rinsed in deionized water.
In order to avoid unspecific binding of streptavidin endogenous
biotin were blocked with the AP-anti-Biotin from the ZytoFast
HPV-Typing Kit. Blocking was carried out for 30 min at 37uC.
Hybridization of biotinylated HPV type 6/11, 16/18, and 31/33
specific DNA probes was carried out with an initial denaturation
for 10 min at 75uC, and hybridization for 1 hour at 37uC.
Unhybridized probes were removed by washing in TBS and
distilled water, and PE-conjugated streptavidin was applied with a
30 min incubation at 37uC, followed by a thoroughly washing.
Finally, 49,6-diamidino-2-phenylindole dihydrochloride (DAPI)
(300 mM) (Sigma-Aldrich, Brøndby, Denmark) was applied for
5 min without subsequent washing. Cover slips were mounted
with a mix of polyvinyl alcohol and glycerol, and the microscope
slides were analyzed on a Zeiss confocal microscope with a 636
magnification. The specificity of the fluorescent signal was verified
by including preparations from three HPV-negative (as deter-
mined with the HPV array) semen samples probed with a mix of
all three HPV probes and by checking for convergence of signaling
through channels capturing wavelengths different from those
excited by PE.
Results
Semen samples from 188 healthy Danish sperm donors were
analyzed for the presence of 20 high-risk and 15 low-risk types of
HPV (Figures 1A and 1B). From 10.6% (20/188) of the donors
high-risk HPV types could be detected, whereas low-risk types
were detected in 8.0% (15/188) of donors. Among the high-risk
types, HPV-51 and -52 were most frequently detected (each 2.7%
(5/188)), whereas HPV-16 was found in 2.1% (4/188) of the
donors (Figure 1A). Among low-risk types, HPV-6 was detected in
3.2% (6/188) and HPV-84 in 2.1% (4/188) of donors (Figure 1B).
Taken together, 16.0% (30/188) of sperm donors were positive for
the tested HPV types and 10 of the donors (5.3%) had double or
triple HPV infections (8 double and 2 triple). Semen donor positive
for HPV was in 33.3% (10/30) of the cases infected with additional
HPV types. Among all the detected HPV types, 61.9% (26/42)
were high-risk types and 38.1% (16/42) were low-risk types.
Despite donor acceptance criteria such as restricted sexual
behavior and no current or previous signs of genital HPV
infection, no significant difference in positivity was observed
between selected and unselected donors (15.8% (18/114) versus
16.2% (12/74), respectively).
From the 188 donors, a total of 267 ejaculates were analyzed for
presence of 35 types of HPV. Series of 8–10 ejaculates from 6
different donors delivered over various time ranges revealed an
inconsistent pattern of viral shedding in the semen (Figure 2).
To address whether in vivo association between HPV sperm
was present, we took advantage of samples already characterized
for the presence of HPV. Sperm samples positive for HPV-6,
HPV-16, HPV-18, or HPV-31 were hybridized with a specific
probe against the respective type, and the HPV-probe-sandwiches
were visualized (Figures 3A–3I and 4). This revealed characteristic
protrusions at or near the equatorial segment of the sperm head
(Figures 3A–C). Likewise, when sperm from HPV-6, -18, or -31
Figure 4. Binding pattern of HPV to sperm using fluorescence in situ hybridization with HPV type-specific probes. (A–C): Close-up
picture of sperm of which one is positive for HPV type 18. Picture B shows the sperm present in picture A, captured by differential interference
contrast (DIC). Picture C shows an overlay of A and B. (D): Close-up picture of HPV-negative and HPV-18 positive sperm cell from an HPV-18-positive
semen sample stained for HPV (red) and DNA (blue). Note the lack of DNA staining characteristic of the majority of HPV positive sperm. Lack of or
decreased DNA staining was seen in all HPV-positive sperm.
doi:10.1371/journal.pone.0018095.g004
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probes, similar protrusions were identified (Figures 3D–I and 4).
However, when sperm from an HPV negative donor were
hybridized with an HPV specific probe, there was no specific
binding (Figures 3J–L and 4). HPV-infected tonsil biopsies were
included as positive controls (data not shown). These data indicate
that HPV-6, -16, -18, and -31 bind to the sperm cell head
particularly at or near the equatorial segment in vivo.
Interestingly, fluorescence in situ hybridization results revealed
decreased DAPI staining of all sperm binding HPV, the majority
with no detectable DAPI stain (Figures 4C and D).
Three fourths of samples, which could be semi-quantified by
FISH and the available probes, were chosen for quantification by
manual counting. In Figure 5, the frequency of HPV-positive
sperm in ejaculates from three donors is illustrated. A total of 2196
sperm were counted from 9 HPV-positive donors giving an overall
mean of HPV-positive sperm of 7.4% and a median of 5%. The
range was 1–16.5%.
Discussion
Despite the likely pathogenic importance of oncogenic HPV
types in semen, the frequency of high-risk and low-risk HPV types
in healthy semen donors has not received much attention. A very
recent paper on 60 semen samples from healthy individuals found
that 3.3% contained HPV [24]. We used a sensitive HPV array to
detect 35 types, encompassing 20 high-risk and 15 low-risk types of
HPV. The HPV types included in this array constitute the most
common ano-genital types. We cannot exclude, however, that our
HPV-negative semen samples might contain HPV types different
from the ones recognized by the array, but the majority of the non-
included HPV types gives cutaneous infections and are therefore
not likely to be found in semen or persist inside genitals. We found
that 16% of healthy semen donors harbor HPV in their semen and
11% of semen samples harbor high-risk types.
On average, we found that HPV-positive samples contained
7.4% HPV-positive sperm. However, this number varied consid-
erably from 1–16.5% and moreover, we do not know how much
HPV DNA is needed to give a positive signal in our fluorescence in
situ hybridization analysis. We have not determined the viral load
in the samples, since no international consensus as to the relevance
of viral load for HPV infection has been agreed upon, and to our
knowledge no qPCR has been clinically validated. Thus, the
significance of HPV transmission from HPV-positive semen versus
direct mucosal contact remains to be determined. Anyhow, semen
cannot be excluded as a possible risk factor for HPV transmission
and testing donor semen for HPV should be considered.
The finding of HPV in 16% of semen samples is comparable
with a recent paper on HPV frequency in Danish women [25]. In
this study, an overall HPV prevalence of 26% was found with a
peak incidence of 50% in women between 20 and 24 years of age.
Among all age groups, high-risk HPV types were found in 19% of
women with normal cytology.
The prevalence of HPV types may vary with the geographical
locations. In men from Africa, less than 55% of the high-risk types
were among HPV types 16, 18, 31, 33, 45, 52, and 58 [5]. The
most prevalent high-risk types in our analysis were HPV types 51,
Figure 5. Frequency of HPV-positive sperm using fluorescence in situ hybridization with HPV type-specific probes. Low magnification
pictures illustrating the quantity of HPV in positive semen samples. Samples are positive for HPV-6, -16, -18, and -31, respectively. Samples are stained
for HPV with PE-conjugated streptavidin (red) and stained for DNA with DAPI (blue). Pictures are representatives of coincidental spots of the
preparation slides, which are representatives of HPV positive semen samples from 9 donors (HPV-6, -16, -18, and -31 represented by 2–3 donors each).
doi:10.1371/journal.pone.0018095.g005
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detected among our samples. This suggests that investigations as
presented here should be performed at different geographical
locations to get the most adequate picture of the distribution of
HPV types in semen. This is of direct importance for the
development of vaccines, which may need to be designed more
specifically for individual countries.
Using fluorescence in situ hybridization to visualize viral
particles concomitantly with sperm DNA, we noticed a significant
decrease in sperm DNA staining by DAPI, when HPV was
associated. The mechanism for this is unknown, but may be
associated with an HPV-induced apoptosis. Other reports,
however, have stated that HPV is still detectable in sperm samples
after sperm wash [9,12,16] suggesting the possibility of viral
transfer to the cervix and the intrauterine cavity via sperm post
intercourse or during intrauterine insemination (IUI). Regardless
of the viability of the sperm, a transmission of the virus from the
sperm surface to the female cervical epithelia could imaginably
occur through simple contact between the sperm cell and the
epithelia cell. HPV have been isolated from endometrial
carcinomas [26,27], but whether HPV is the causative agent of
these carcinomas remains to be defined. Moreover, an association
between HPV infections and decreased pregnancy rate has been
reported [28].
Considering the general infertility population, assisted repro-
ductive technology procedures, like intracytoplasmic sperm
injection, involve no natural selection of the sperm cell, which
means that these procedures have a plausible risk of injecting
sperm containing HPV. Our observation of HPV-6, -16, -18, and
-31 association to or near the sperm head equatorial segment is
consistent with the finding of Pe ´rez-Andino et al. [22], who
recently showed that pseudovirions of HPV 16 capsid proteins
adsorb to this exact same location on the sperm cell. Thus a
specific receptor for HPV may be located at or near the equatorial
segment.
A proportion of women immunized with the currently available
HPV vaccines may still attract cervical cancer. Besides the role of
HPV in dysplasia of cervix, dysplasia of genital tissues also occurs
in males. This indicates that it may be important to further
characterize the circulating HPV high-risk types in both women
and men. Our data have contributed to increased knowledge of
the distribution pattern of HPV in healthy men. This information
may be useful for improving HPV vaccine coverage.
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